LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Evaluation of respiratory tract bacterial co-infections in SARS-CoV-2 patients with mild or asymptomatic infection in Lagos, Nigeria.

    Davies-Bolorunduro, Olabisi Flora / Fowora, Muinah Adenike / Amoo, Olufemi Samuel / Adeniji, Esther / Osuolale, Kazeem Adewale / Oladele, Oluwatobi / Onuigbo, Tochukwu Ifeanyi / Obi, Josephine Chioma / Oraegbu, Joy / Ogundepo, Oluwatobi / Ahmed, Rahaman Ademolu / Usman, Olagoke AbdulRazaq / Iyapo, Bosede Ganiyat / Dada, Adedamola Adejuwon / Onyia, Ngozi / Adegbola, Richard Adebayo / Audu, Rosemary Ajuma / Salako, Babatunde Lawal

    Bulletin of the National Research Centre

    2022  Volume 46, Issue 1, Page(s) 115

    Abstract: Background: A common complication of any respiratory disease by a virus could be a secondary bacterial infection, which is known to cause an increase in severity. It is, however, not clear whether the presence of some opportunistic pathogens called ... ...

    Abstract Background: A common complication of any respiratory disease by a virus could be a secondary bacterial infection, which is known to cause an increase in severity. It is, however, not clear whether the presence of some opportunistic pathogens called pathobionts contributes to the severity of the disease. In COVID-19 patients, undetected bacterial co-infections may be associated with the severity of the disease. Therefore, we investigated the implications of bacterial co-infections in COVID-19 cases.
    Results: This is a cross-sectional study that involved archived specimens collected from nasopharyngeal samples of 150 people for COVID-19 screening in Lagos. DNA extraction from the samples was carried out to determine the presence of five respiratory bacterial pathogens using nested real-time PCR, and data were analysed using the Chi-square test. Of the 150 samples collected, 121 (80.7%) were positive for SARs-CoV-2 infection and 29 were negative. The proportion of patients with bacteria co-infection in COVID-19-negative, asymptomatic, and mild cases were 93.1%, 70.7%, and 67.5%, respectively. There was no statistically significant difference between mild COVID-19 conditions and bacteria co-infection (
    Conclusions: The current study shows that bacterial co-infection and superinfection with COVID-19 are not associated with mild and asymptomatic COVID-19 cases in our setting. However, given the high prevalence of
    Language English
    Publishing date 2022-04-21
    Publishing country Germany
    Document type Journal Article
    ISSN 2522-8307
    ISSN (online) 2522-8307
    DOI 10.1186/s42269-022-00811-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: COVID-19 vaccine breakthrough infections among fully vaccinated Health Care Workers in Lagos, Nigeria

    Oladele, David Ayoola / Salako, Abideen / Ayorinde, James / Onwuamah, Chika / Usman, Olagoke / Abubakar, Rufai / Liboro, Gideon / Odubela, Oluwatosin / Mogaji, Sunday / Ige, Fehintola / Ohihoin, Gregory / Ezechi, Oliver / Audu, Rosemary / Adegbola, Richard A. / Dada, Adedamola / Salako, Tunde

    medRxiv

    Abstract: Background Access to vaccines has contributed to the control of COVID-19. However, evaluation of the effectiveness of the vaccines in a setting where the vaccines were not originally tested is critically important. This study evaluates the clinical and ... ...

    Abstract Background Access to vaccines has contributed to the control of COVID-19. However, evaluation of the effectiveness of the vaccines in a setting where the vaccines were not originally tested is critically important. This study evaluates the clinical and laboratory characteristics of COVID-19 vaccine breakthrough infections among healthcare workers (HCWs). Methods A multicentre prospective study among HCWs who had two doses of the Oxford/AstraZeneca ChAdOx1-S [recombinant] (AZD1222) vaccine were followed up 24 weeks. Nasopharyngeal and oropharyngeal specimens were tested using RT-PCR for SARS-CoV-2 and positive samples were subjected to whole genome sequencing for variant assignment. Result A total of 369 HCWs were enrolled; of which 24 (6.5%) had breakthrough infections. There was equal sex distribution among the breakthrough cases. The majority were aged between 30 to 39years (37.5%), and had mild symptoms of cough, fever, headache, and nausea/vomiting (58%), with no hospitalization. Among the 24 breakthrough cases whose whole genomes were successfully sequenced, three were confirmed to be Delta B.1.617.2 variant during the 3 rd wave and an additional three were confirmed as omicron B.1.1.529 variant during the 4 th wave. Conclusion We reported vaccine breakthrough cases among fully vaccinated HCWs with the majority presenting with mild illness. Both delta and omicron variants were identified during the different epidemiologic spectrums of SARS-CoV-2. Therefore, there is a need to scale up vaccination for all front-line health workers and high-risk populations in developing countries.
    Keywords covid19
    Language English
    Publishing date 2022-06-22
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2022.06.22.22276765
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Antibody responses to AZD1222 vaccination in West Africa

    Abdullahi, Adam / Oladele, David / Kemp, Steven / Ayorinde, James / Salako, Abideen / Ige, Fehintola / Fink, Douglas / Onwuamah, Chika / Osuolale, Qosim / Abubakar, Rufai / Okuruawe, Azuka / Liboro, Gideon / Odubela, Oluwatosin / Ohihoin, Gregory / Ezechi, Oliver / Usman, Olagoke / Mogaji, Sunfay / Dada, Adedamola / Ebrahimi, Soraya /
    Gutierrez, Lourdes Ceron / Aliyu, Sani H / Doffinger, Rainer / Audu, Rosemary / Adegbola, Richard / Mlcochova, Petra / Salako, Babatunde Lawal / Gupta, Ravindra K

    medRxiv

    Abstract: Background: There are no data on vaccine elicited neutralising antibody responses for the most widely used vaccine, AZD1222, in African populations following scale up. Here, we measured i. baseline SARS-CoV-2 seroprevalence and levels of protective ... ...

    Abstract Background: There are no data on vaccine elicited neutralising antibody responses for the most widely used vaccine, AZD1222, in African populations following scale up. Here, we measured i. baseline SARS-CoV-2 seroprevalence and levels of protective antibodies prior to vaccination rollout using both flow cytometric based analysis of binding antibodies to nucleocapsid (N), coupled with virus neutralisation approaches and ii. neutralizing antibody responses to VOC prior to vaccination (January 2021) and after two-doses of AZD1222 vaccine administered between June and July 2021 in Lagos, Nigeria, during a period when the Delta variant was also circulating. Methods: Health workers at multiple sites in Lagos were recruited to the study. For binding antibody measurement, IgG antibodies against SARS-COV-2 Wuhan-1 receptor-binding domain (RBD), trimeric spike protein (S), nucleocapsid protein (N) and Omicron S1 were measured using the Luminex-based SARS-CoV-2-IgG assay by flow cytometry. For plasma neutralising antibody measurement, SARS-CoV-2 lentiviral pseudovirus (PV) were prepared by transfecting 293T cells with Wuhan-614G wild type (WT), B.1.617.2 (Delta) and BA.1 (Omicron) plasmids in conjunction with HIV-1 expression vectors and luciferase encoding genome flanked by LTRs. We performed serial plasma dilutions from each time point and mixed plasma with PV before infecting HeLa-ACE2 cell lines, reading out luminescence and calculating ID50 (dilution of sera required to inhibit 50% of PV infection). Results: Our study population who received at least one dose of vaccine comprised 140 participants with a median age of 40 (interquartile range: 33, 48). 62/140 (44%) participants were anti-N IgG positive prior to administration of first vaccine dose. 49 had plasma samples available at baseline prior to vaccination and at two follow-up timepoints post vaccination for neutralization assays. Half of the participants, 25/49 (51%) were IgG anti-N positive at baseline. Of the 24 individuals anti-N Ab negative at baseline, 12/24 had ID50 above the cut-off of 20. In these individuals, binding antibodies to S were also detectable, and neutralisation correlated with IgG anti-S. Overall, neutralizing Ab titres to WT 1 month after second dose were 2579 and at 3 months post second-dose were 1695. As expected, lower levels of neutralization were observed against the Delta GMT 549 and Omicron variants 269 at 1 month. Positive anti-N IgG Ab status at baseline was associated with significantly higher titres of neutralizing antibodies following vaccination across all tested VOC. Those with anti-N Abs present at baseline did not experience waning of responses between months 1 and 3 post second dose. When data were analysed for negative anti-N IgG status at any timepoint, there was a significant decline in neutralization and binding antibodies between 1 month and 3 months post second-dose. The GMT in these individuals for Delta and Omicron was approximately 100, nearly a log lower in comparison to WT. We tested anti-N IgG in subjects who were anti-N IgG negative at baseline (n=78) and became positive between 1- and 3-months post second dose and found 7/49 (14%) with de-novo infection, with one additional participant demonstrating both reinfection and breakthrough infection to yield a total breakthrough rate of 8/49 (16%). Neutralising and binding Ab titres 1 month post vaccine, prior to breakthrough, did not appear to be associated with breakthrough infection. Neutralizing titres were higher at the last time point in individuals who had experienced vaccine breakthrough infection (with no evidence of infection prior to vaccine), indicating a boosting effect of infection in addition to vaccine. We noted that the increase in titres against Delta PV observed in breakthrough was significantly greater than the increase for WT and Omicron PVs, coincident with in the Delta wave of infection during the sampling period. Conclusions: AZD1222 is immunogenic in this real world west African cohort with significant background seroprevalence and incidence of breakthrough infection over a short time period. Prior infection and breakthrough infection induced higher anti-SARS-CoV-2 Ab responses at 3 months post vaccine against all widely circulating VOC. However, responses to Omicron BA.1 were reduced at three months regardless of prior exposure. Given that data suggesting that mRNA vaccine booster third doses induce broader, more potent responses with reduced mortality in the elderly, further doses after AZD1222 should be considered for those at high risk.
    Keywords covid19
    Language English
    Publishing date 2022-05-05
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2022.05.04.22274668
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa.

    Abdullahi, Adam / Oladele, David / Owusu, Michael / Kemp, Steven A / Ayorinde, James / Salako, Abideen / Fink, Douglas / Ige, Fehintola / Ferreira, Isabella A T M / Meng, Bo / Sylverken, Augustina Angelina / Onwuamah, Chika / Boadu, Kwame Ofori / Osuolale, Kazeem / Frimpong, James Opoku / Abubakar, Rufai / Okuruawe, Azuka / Abdullahi, Haruna Wisso / Liboro, Gideon /
    Agyemang, Lawrence Duah / Ayisi-Boateng, Nana Kwame / Odubela, Oluwatosin / Ohihoin, Gregory / Ezechi, Oliver / Kamasah, Japhet Senyo / Ameyaw, Emmanuel / Arthur, Joshua / Kyei, Derrick Boakye / Owusu, Dorcas Ohui / Usman, Olagoke / Mogaji, Sunday / Dada, Adedamola / Agyei, George / Ebrahimi, Soraya / Gutierrez, Lourdes Ceron / Aliyu, Sani H / Doffinger, Rainer / Audu, Rosemary / Adegbola, Richard / Mlcochova, Petra / Phillips, Richard Odame / Solako, Babatunde Lawal / Gupta, Ravindra K

    Nature communications

    2022  Volume 13, Issue 1, Page(s) 6131

    Abstract: Real-world data on vaccine-elicited neutralising antibody responses for two-dose AZD1222 in African populations are limited. We assessed baseline SARS-CoV-2 seroprevalence and levels of protective neutralizing antibodies prior to vaccination rollout ... ...

    Abstract Real-world data on vaccine-elicited neutralising antibody responses for two-dose AZD1222 in African populations are limited. We assessed baseline SARS-CoV-2 seroprevalence and levels of protective neutralizing antibodies prior to vaccination rollout using binding antibodies analysis coupled with pseudotyped virus neutralisation assays in two cohorts from West Africa: Nigerian healthcare workers (n = 140) and a Ghanaian community cohort (n = 527) pre and post vaccination. We found 44 and 28% of pre-vaccination participants showed IgG anti-N positivity, increasing to 59 and 39% respectively with anti-receptor binding domain (RBD) IgG-specific antibodies. Previous IgG anti-N positivity significantly increased post two-dose neutralizing antibody titres in both populations. Serological evidence of breakthrough infection was observed in 8/49 (16%). Neutralising antibodies were observed to wane in both populations, especially in anti-N negative participants with an observed waning rate of 20% highlighting the need for a combination of additional markers to characterise previous infection. We conclude that AZD1222 is immunogenic in two independent West African cohorts with high background seroprevalence and incidence of breakthrough infection in 2021. Waning titres post second dose indicates the need for booster dosing after AZD1222 in the African setting despite hybrid immunity from previous infection.
    MeSH term(s) Antibodies, Neutralizing ; Antibodies, Viral ; Antibody Formation ; COVID-19/epidemiology ; COVID-19/prevention & control ; ChAdOx1 nCoV-19 ; Ghana ; Humans ; Immunoglobulin G ; SARS-CoV-2 ; Seroepidemiologic Studies ; Vaccination ; Viral Vaccines
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Immunoglobulin G ; Viral Vaccines ; ChAdOx1 nCoV-19 (B5S3K2V0G8)
    Language English
    Publishing date 2022-10-17
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-022-33792-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Implementation of a Non-Invasive Helmet Ventilation Solution for the Management of Severe COVID-19 Respiratory Disease in Nigeria: The CircumVent Project

    Ahonkhai, Aima A. / Abdu, Aliyu / Adekanmbi, Olukemi / Ajayi, Nnennaya A. / Ajayi, Samuel / Akpobi, Happy / Akpochafo, Ejiro Benjamin / Aliyu, Muktar H. / Ayuk, Adaeze C. / Dada, Adedamola A. / Ezechi, Oliver C. / Falade, Catherine O. / Horstein, Alex / Olusola, Idowu / Idigbe, Ifeoma / Mogaj, Sunday / Morenikeji, Aleem A. / Musa, Baba M. / Nwosu, Nnamdi I. /
    Odewabi, Adenike A. / Ofokotun, Igho / Ogedegbe, Gbenga / Ogueh, Onome / Oyewole, Temitope O / Sotannde, Adeshola I. / Steinbach, Alan B. / Ulasi, Ifeoma I. / Ukwaj, Kingsley N. / Unigwe, Uchechukwu S. / Usman, Olagoke A. / Uzoke, Cyril / Musa, Adesola Z. / Rotimi, Muyiwa K. / Akase, Iorhen E. / Adeyemo, Wasiu L. / Fenton, Andre A. / Salako, Babatunde L.

    medRxiv

    Abstract: Affordable novel strategies are needed to treat COVID-19 cases complicated by respiratory compromise in resource limited settings. We report a mixed-methods pre-post assessment of 1) the useability of CPAP/O2 helmet non-invasive ventilation (NIV) to ... ...

    Abstract Affordable novel strategies are needed to treat COVID-19 cases complicated by respiratory compromise in resource limited settings. We report a mixed-methods pre-post assessment of 1) the useability of CPAP/O2 helmet non-invasive ventilation (NIV) to treat COVID-19, at ~1% the cost of mechanical ventilation; 2) the effectiveness of a train-the-trainer practice facilitation intervention; and 3) whether use of CPAP/O2 helmet NIV was associated with increased COVID-19 infection among healthcare workers. At baseline, eight COVID-19 treatment centers in Nigeria (CircumVent network) received CPAP/O2 helmet systems, and were instructed on its use. After five months, clinicians within the CircumVent netwok participated in a 2-day train-the-trainers educational intervention. The physicians completed i) standardized forms on patient demographics, clinical course, and outcomes for patients seen in the treatment centers; ii) standardized surveys of feasibility and acceptability of use of CPAP/O2 helmet systems; and iii) in-depth-interviews to explore facilitators and barriers to implementation of CPAP/O2 helmet NIV. Physicians described the CPAP/O2 helmet ventilator as easy to use and they felt comfortable training their staff on its use. They rated CPAP/O2 helmet NIV as feasible, acceptable, and appropriate (mean score of 4.0, 3.8, and 3.9 out of 5, respectively, on standardized scales). Case report forms for 546 patients with suspected and/or confirmed COVID-19 infection were obtained between May 2020 and November 2021. Of these, 69% (n=376) were treated before the training; and 29.7% (n=162) were treated with CPAP/O2 helmet ventilation. CPAP/O2 helmet NIV was well-tolerated by patients, with 12% reporting claustrophobia, and 2% reporting loose- or tight-fitting helmets. Although patient outcomes improved among CPAP/O2 helmet users overall, this was not associated with training (P=0.2). This finding persisted after adjustment for disease severity at presentation. Serosurvey of 282 health workers across treatment centers revealed that 40% (n=112) were seropositive for SARS-CoV-2. Seropositivity was significantly associated with direct contact with COVID-19 patients and limited access to PPE and hand hygiene during aerosol generating procedures (P = 0.02), but not use of CPAP/O2 helmet (Ps ≥ 0.2). In conclusion, physicians effectively used CPAP/O2 helmet NIV systems to treat COVID-19 patients in Nigeria without need for practice facilliation of their training and without increased risk of infection among healthcare workers. The use of CPAP/O2 helmet NIV could be an important strategy for treating individuals with COVID-19 infection and other disease conditions complicated by respiratory distress, particularly in settings were resources such mechanical ventilation are limited.
    Keywords covid19
    Language English
    Publishing date 2022-09-01
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2022.08.30.22279372
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top